CONSULTING AGREEMENTConsulting Agreement • March 3rd, 2020 • BridgeBio Pharma, Inc. • Pharmaceutical preparations • California
Effective October 14, 2019 (the “Effective Date”), Jennifer Cook Consulting (“Consultant”) and BridgeBio Services, Inc., a Delaware corporation, agree as follows:
COLLABORATION AGREEMENT by and between BridgeBio GENE THERAPY, LLC andCollaboration Agreement • March 3rd, 2020 • BridgeBio Pharma, Inc. • Pharmaceutical preparations • Delaware
THIS COLLABORATION AGREEMENT (this “Agreement”), dated as of the 31st day of December, 2019 (the “Effective Date”), is entered into by and among Bridgebio gene therapy, LLC, a limited liability corporation organized and existing under the Laws of Delaware and having a place of business at 421 Kipling Street, Palo Alto, California 94301, (“BridgeBio”) and CATALENT MARYLAND, INC. (formerly Paragon Bioservices, Inc.), a corporation organized and existing under the Laws of Delaware and having a place of business at 801 West Baltimore Street, Suite 302, Baltimore, Maryland 21201 (“Catalent”). BridgeBio and Catalent are sometimes referred to herein, individually, as a “Party” and, collectively, as the “Parties.” All capitalized terms used herein, including in the Exhibits and Schedules hereto, shall have the meanings specified in Exhibit A attached hereto or elsewhere in this Agreement, as applicable, unless otherwise specified.
FOURTH AMENDMENT to the Exclusive License Agreement Effective September 28, 2016 Between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA And THERAS, INC.BridgeBio Pharma, Inc. • March 3rd, 2020 • Pharmaceutical preparations
Effective December 16, 2019, (the “Fourth Amendment Effective Date”) THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (“THE REGENTS”), a California corporation, having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200 and acting through its Office of Technology Management, University of California San Francisco (“UCSF”), 600 16th Street, Suite S-272, San Francisco, CA 94143 and TheRas, Inc., a Delaware corporation, having a principal place of business at 421 Kipling Street, Palo Alto, CA 94301 (“LICENSEE”), agree as follows:
